Markets open

Revolution Medicines, Inc.

RVMD · Nasdaq

Analyst Consensus

Buy

13 analysts

$195

Current

—

Low

$210

Average

—

High

Average target implies +7.89% versus the current price.

The ratings synthesis for RVMD has not been generated yet.

Rating Actions

No individual rating actions have been captured for RVMDyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Covering Firms

B OF A GLBL RES

GOLDMAN SACHS

GUGGENHEIM SEC.

H C WAINWRIGHT

JP MORGAN SECUR

LEERINK PARTNRS

NEEDHAM & CO.

OPPENHEIMER HLD

RAYMOND JAMES

STIFEL NICOLAUS

TD COWEN

UBS

WEDBUSH SECURIT

Symbol: RVMD
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: North America
Exchange: Nasdaq

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).